Opicapone is Used for treating Parkinson's disease by providing adjunctive therapy to patients experiencing off episodes in combination with levodopa/carbidopa. It was first introduced by Amneal Pharmaceuticals Llc in its drug Ongentys on Apr 24, 2020.

Opicapone Patents

Given below is the list of patents protecting Opicapone, along with the drug name that holds that patent and the company name owning that drug.

Download patent list as spreadsheet

Get the complete list right in your inbox!

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Ongentys	US10357468	Medicaments for slowing Parkinson's disease	May 27, 2035	Amneal
Ongentys	US9630955	Chemical compound useful as intermediate for preparing a catechol-O-methyltransferase inhibitor	Dec 12, 2032	Amneal
Ongentys	US12129247	Administration regime for nitrocatechols	Jan 11, 2032	Amneal
Ongentys	US10071085	Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof	Mar 31, 2030	Amneal
Ongentys	US10583130	Pharmaceutical formulations compromising nitrocatechol derivatives and methods of making thereof	Mar 31, 2030	Amneal
Ongentys	US8524746	Dosage regimen for COMT inhibitors	Jul 14, 2029	Amneal
Ongentys	US8168793	Nitrocatechol derivatives as COMT inhibitors	Apr 02, 2029	Amneal
Ongentys	US9745290	Dosage regimen for COMT inhibitors	Oct 10, 2027	Amneal
Ongentys	US8907099	Nitrocatechol derivatives as COMT inhibitors	May 12, 2027	Amneal
Ongentys	US9550759	Nitrocatechol derivatives as COMT inhibitors	Jul 26, 2026	Amneal

Add above patents to watchlist

Opicapone's Family Patents

Full family tree